{"product_id":"kirinholdings-business-model-canvas","title":"Kirin Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKirin Business Model Canvas: Downloadable Playbook for Investors \u0026amp; Founders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Kirin’s strategic blueprint with our Business Model Canvas—clearly mapping value propositions, customer segments, key partners, and revenue streams to show how the company competes and scales; perfect for investors, consultants, and founders who need actionable, ready-to-use analysis—download the full Word\/Excel canvas to benchmark, plan, and replicate proven strategies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Alliance with Fancl Corporation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKirin holds a capital and business alliance with Fancl Corporation to bolster its Health Science unit, including a ¥5.0bn equity stake disclosed in 2023 and joint R\u0026amp;D investments of ~¥1.2bn in 2024 for co-developing functional skincare and supplements using Kirin’s fermentation tech.\u003c\/p\u003e\n\u003cp\u003eBy integrating Fancl’s DTC (direct-to-consumer) platform—over 2.4m loyalty members in 2024—Kirin expanded wellness channel reach, aiming for a combined Health Science revenue target of ¥40bn by FY2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Research Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThrough subsidiary Kyowa Kirin, Kirin holds global pharma partnerships with biotech and universities to co-develop next‑gen antibody platforms and rare‑disease therapies; as of 2025 Kyowa Kirin reported JPY 214.8 billion in pharma R\u0026amp;D commitments and over 30 active collaborations, sharing clinical risk and milestone economics to keep a steady late‑stage pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution and Bottling Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKirin depends on a global network of distributors and local bottlers to keep market share abroad; in 2024 this network supported export volumes of ~1.2 million hectoliters and international sales of JPY 180 billion (about USD 1.2 bn). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgricultural and Raw Material Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe company secures long-term contracts with farmers for hops, malt, and adjuncts, investing in sustainable practices and climate-resilient supply chains after a 2024 pilot cut water use by 18% and raised hop yield 12%.\u003c\/p\u003e\n\u003cp\u003eCollaborations include technical support to growers to keep Kirin Ichiban quality consistent; procurement aims to source 60% sustainable ingredients by 2030 per Kirin Group targets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLong-term contracts with growers\u003c\/li\u003e\n\u003cli\u003e2024 pilot: −18% water, +12% hop yield\u003c\/li\u003e\n\u003cli\u003eTechnical support for consistency\u003c\/li\u003e\n\u003cli\u003eTarget: 60% sustainable sourcing by 2030\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJoint Ventures in Logistics and Sustainability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKirin joins logistics joint ventures with other beverage makers to cut delivery miles and CO2; a 2024 pilot cut route km 12% and emissions 9%, saving about ¥350 million in fuel and driver costs.\u003c\/p\u003e\n\u003cp\u003eSharing trucks raises load factors to ~85% vs 60% solo, helping meet Kirin’s 2030 target of 30% Scope 3 reduction and offset rising Japanese fuel\/labor costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12% fewer km, 9% CO2 cut (2024 pilot)\u003c\/li\u003e\n\u003cli\u003e¥350M fuel\/labor savings (2024)\u003c\/li\u003e\n\u003cli\u003eLoad factor up to ~85% vs 60%\u003c\/li\u003e\n\u003cli\u003eSupports 2030 Scope 3 −30% target\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKirin’s partnerships: scaling Health Science to ¥40bn, ¥215bn pharma R\u0026amp;D \u0026amp; sustainability gains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKirin’s key partnerships span a ¥5.0bn equity+¥1.2bn R\u0026amp;D alliance with Fancl (2023–24) to scale Health Science to a ¥40bn FY2026 target, Kyowa Kirin’s 30+ pharma collaborations with JPY 214.8bn R\u0026amp;D commitments (2025), global distributors exporting ~1.2M hl and JPY 180bn sales (2024), farmer contracts targeting 60% sustainable sourcing by 2030, and logistics JVs cutting km 12%\/CO2 9% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003eYear\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFancl\u003c\/td\u003e\n\u003ctd\u003e¥5.0bn equity; ¥1.2bn R\u0026amp;D; target ¥40bn HS revenue\u003c\/td\u003e\n\u003ctd\u003e2023–2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKyowa Kirin\u003c\/td\u003e\n\u003ctd\u003e30+ collaborations; JPY 214.8bn R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributors\u003c\/td\u003e\n\u003ctd\u003e~1.2M hl; JPY 180bn sales\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGrowers\u003c\/td\u003e\n\u003ctd\u003e−18% water\/+12% hop yield pilot; 60% sustainable by 2030\u003c\/td\u003e\n\u003ctd\u003e2024–2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics JVs\u003c\/td\u003e\n\u003ctd\u003e−12% km; −9% CO2; ¥350M savings\u003c\/td\u003e\n\u003ctd\u003e2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Kirin that maps nine BMC blocks with clear value propositions, customer segments, channels and revenue streams aligned to real-world brewing, beverages and health science operations, ideal for investor presentations and strategic planning with linked SWOT insights and competitive advantage analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Kirin’s strategy into a clean, editable one-page Business Model Canvas to save hours of structuring and enable fast boardroom-ready comparisons and collaborative adaptation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Fermentation and Biotechnology R and D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKirin invests ~¥60bn annually in R\u0026amp;D (2024), centering on advanced fermentation and biotech across beer, health sciences, and pharmaceuticals to scale proprietary ingredients like LC-Plasma; this R\u0026amp;D drove ¥12.4bn revenue from health-related products in FY2023 and supports product differentiation via clinically shown immune benefits in multiple randomized trials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand Management and Global Marketing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA core activity is strategic positioning and promotion of the Kirin brand across markets, with FY2024 group advertising and promotion spend about JPY 96.5 billion to support both premium beers (Kirin, Ichiban) and functional drinks (Kirin Beverage), requiring tailored campaigns per segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Quality Control Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpkirin operates dozens of production sites across japan and asia enforcing iso food-safety in-house qc protocols to keep product consistency for kirin ichiban afternoon tea in capital expenditure on manufacturing quality control totaled billion about group capex. the company is automating lines cells ai vision takt time by pilot plants offsetting a year-on-year decline factory labor availability.\u003e\n\u003c\/pkirin\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Commercialization and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eKirin oversees clinical trials, secures approvals, and commercializes drugs via Kyowa Kirin, which deployed specialized sales teams across Japan, Europe, and the US and reported ¥285.6bn pharma revenue in FY2024 (year to Mar 2025), up 8% YoY, driving the group’s shift to life sciences and higher-margin recurring sales.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinical\/regulatory management\u003c\/li\u003e\n\u003cli\u003eKyowa Kirin global sales force\u003c\/li\u003e\n\u003cli\u003e¥285.6bn pharma revenue FY2024\u003c\/li\u003e\n\u003cli\u003e8% YoY growth\u003c\/li\u003e\n\u003cli\u003eKey long-term profitability driver\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Environmental Sustainability Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpkirin optimizes its end-to-end supply chain to cut waste and shrink packaging emissions rolling out recycled pet bottles across japan using brewery water-saving tech that reduced water use per hectoliter by versus levels. managing these programs is now core corporate strategy with kirin targeting net-zero scope allocating billion sustainability investments.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003e100% recycled PET deployment in 2024 rollouts\u003c\/li\u003e\n\u003cli\u003eWater use down 18% per hL since 2018\u003c\/li\u003e\n\u003cli\u003eNet-zero scope 1\/2 target: 2035\u003c\/li\u003e\n\u003cli\u003e¥30 billion sustainability capex (2024–2026)\u003c\/li\u003e\n\n\u003c\/pkirin\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKirin: ¥60bn R\u0026amp;D, ¥96.5bn marketing, ¥285.6bn pharma, automated CAPEX \u0026amp; green push\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKirin runs R\u0026amp;D (~¥60bn\/2024), global brand marketing (¥96.5bn\/2024),  dozens of automated production sites (CAPEX ¥45.2bn\/2024), Kyowa Kirin pharma commercialization (¥285.6bn revenue FY2024, +8% YoY), and sustainability programs (100% recycled PET 2024, −18% water per hL vs 2018, ¥30bn sostenability capex 2024–26).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003eKey 2024–25 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e¥60bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketing\u003c\/td\u003e\n\u003ctd\u003e¥96.5bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing CAPEX\u003c\/td\u003e\n\u003ctd\u003e¥45.2bn (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma revenue\u003c\/td\u003e\n\u003ctd\u003e¥285.6bn FY2024 (+8%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSustainability\u003c\/td\u003e\n\u003ctd\u003e100% PET, −18% water, ¥30bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Kirin Business Model Canvas preview shown here is the actual deliverable—not a mockup or sample—and reflects the same structure and content you will receive after purchase.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you’ll get the full, editable file in the same format, ready for presentation, editing, and implementation with no hidden sections or surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749751730553,"sku":"kirinholdings-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/kirinholdings-business-model-canvas.png?v=1772217905","url":"https:\/\/growthsharematrix.com\/products\/kirinholdings-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}